Vericel Corporation (VCEL)’s Financial Results Comparing With OncoCyte Corporation (NYSEAMERICAN:OCX)

As Biotechnology businesses, Vericel Corporation (NASDAQ:VCEL) and OncoCyte Corporation (NYSEAMERICAN:OCX), are affected by compare. This especially applies to their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vericel Corporation 94.64M 7.44 3.32M -0.09 0.00
OncoCyte Corporation N/A 0.00 15.84M -0.42 0.00

Table 1 shows the top-line revenue, earnings per share and valuation for Vericel Corporation and OncoCyte Corporation.

Profitability

Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Vericel Corporation -3.51% -3.4% -2.6%
OncoCyte Corporation 0.00% -235% -125.5%

Volatility and Risk

Vericel Corporation has a 2.82 beta, while its volatility is 182.00% which is more volatile than S&P 500. Competitively, OncoCyte Corporation’s 539.00% volatility makes it more volatile than S&P 500, because of the 6.39 beta.

Liquidity

8.5 and 8.2 are the respective Current Ratio and a Quick Ratio of Vericel Corporation. Its rival OncoCyte Corporation’s Current and Quick Ratios are 1.6 and 1.6 respectively. Vericel Corporation has a better chance of clearing its pay short and long-term debts than OncoCyte Corporation.

Analyst Recommendations

The table shown features the ratings and recommendations for Vericel Corporation and OncoCyte Corporation.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Vericel Corporation 0 0 2 3.00
OncoCyte Corporation 0 0 0 0.00

Vericel Corporation’s upside potential currently stands at 40.27% and an $22.5 consensus target price.

Institutional & Insider Ownership

Roughly 85.3% of Vericel Corporation shares are owned by institutional investors while 22.3% of OncoCyte Corporation are owned by institutional investors. Vericel Corporation’s share owned by insiders are 0.7%. Comparatively, insiders own roughly 47.3% of OncoCyte Corporation’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Vericel Corporation -5.02% -7.89% -5.96% 5.77% 27.16% -2.07%
OncoCyte Corporation 12.5% 19.43% 30.57% 165.26% 110% 265.22%

For the past year Vericel Corporation had bearish trend while OncoCyte Corporation had bullish trend.

Summary

Vericel Corporation beats OncoCyte Corporation on 8 of the 10 factors.

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. The company also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.

OncoCyte Corporation focuses on the discovery, development, and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using proprietary sets of genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.